MediciNova (NASDAQ:MNOV – Get Free Report) and Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.
Valuation and Earnings
This table compares MediciNova and Collegium Pharmaceutical”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MediciNova | $920,481.00 | 72.46 | -$12.00 million | ($0.21) | -6.45 |
| Collegium Pharmaceutical | $780.57 million | 1.00 | $62.87 million | $1.00 | 25.19 |
Institutional & Insider Ownership
9.9% of MediciNova shares are owned by institutional investors. 14.0% of MediciNova shares are owned by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares MediciNova and Collegium Pharmaceutical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MediciNova | -1,126.60% | -26.47% | -24.24% |
| Collegium Pharmaceutical | 4.68% | 85.14% | 13.80% |
Analyst Ratings
This is a summary of recent recommendations for MediciNova and Collegium Pharmaceutical, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MediciNova | 1 | 1 | 4 | 1 | 2.71 |
| Collegium Pharmaceutical | 0 | 2 | 7 | 1 | 2.90 |
MediciNova presently has a consensus target price of $7.75, suggesting a potential upside of 471.96%. Collegium Pharmaceutical has a consensus target price of $44.00, suggesting a potential upside of 74.67%. Given MediciNova’s higher probable upside, equities research analysts plainly believe MediciNova is more favorable than Collegium Pharmaceutical.
Risk and Volatility
MediciNova has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.
Summary
Collegium Pharmaceutical beats MediciNova on 10 of the 14 factors compared between the two stocks.
About MediciNova
MediciNova is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries. Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders.
About Collegium Pharmaceutical
Collegium Pharmaceutical is a U.S.-based specialty pharmaceutical company focused on developing and commercializing medicines for pain management. Its portfolio includes Xtampza ER, an extended-release oxycodone product; Belbuca, a buprenorphine buccal film for chronic pain; and Nucynta, tapentadol tablets available in immediate- and extended-release formulations. The company also markets Symproic, a treatment for opioid-induced constipation. Collegium’s products include extended-release and opioid medicines, and the company emphasizes responsible use and risk-mitigation measures in its commercial activities.
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.
